Full history for every metric is available with a Kvantra account
Eiger BioPharmaceuticals, Inc. (EIGR)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 12 | 13 | 16 | 16 |
| Operating profit | $m | -72 | -72 | |||||
| Net profit | $m | -52 | -74 | -69 | -34 | -97 | -75 | -75 |
| EPS reported | $ | -50.78 | -50.81 | |||||
| Operating cashflow per share | $ | -50.50 | -50.50 | |||||
| Capex per share | $ | 0.16 | 0.16 | |||||
| FCF per share | $ | -50.66 | -50.66 | |||||
| Free cash flow | $m | -75 | -75 | |||||
| Net debt | $m | 16 | 16 | |||||
| Book value equity | $m | -14 | -14 | |||||
| Book value per share | $ | -9.79 | -9.79 | |||||
| Number of shares | m | 1.48 | 1.48 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.69 | -0.18 | |||||
| P/S LTM | x | 0.63 | 0.16 | |||||
| P/FCF LTM | x | -0.13 | -0.03 | |||||
| EV/EBITDA LTM | x | -0.37 | -0.27 | |||||
| EV/Sales LTM | x | 1.63 | 1.16 | |||||
| Earnings Yield LTM | % | -753.40% | -2943.7% | |||||
| FCF Yield | % | -751.59% | -2930.2% | |||||
| Quality | ||||||||
| ROE | % | 518.49% | -367.00% | |||||
| ROIC | % | -268.41% | -268.41% | |||||
| Operating margin | % | -455.12% | -455.12% | |||||
| Gross margin | % | 99.85% | 99.85% | |||||
| FCF/Sales | % | -474.11% | -474.11% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +16.98% | +16.98% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.81 | -1.81 | |||||
| Net Debt/EBITDA | x | -0.23 | -0.23 | |||||
| EBIT/Net interest | x | -13.13 | -13.13 | |||||
| Net debt/market cap | % | 157.58% | 614.35% | |||||
| Net debt/Equity | x | -1.08 | -1.08 | |||||
| Gross debt/equity | x | -2.85 | -2.85 | |||||
Company overview
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Eiger BioPharmaceuticals, Inc. (EIGR)
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free